博纳吐单抗用于复发儿童急性淋巴细胞白血病的1/2期研究。 - Suppr

Phase 1/2 study of blinatumomab in relapsed paediatric ALL.

作者信息

Brower Vicki

出版信息

Lancet Oncol. 2016 Dec;17(12):e525. doi: 10.1016/S1470-2045(16)30580-0. Epub 2016 Nov 11.

DOI:10.1016/S1470-2045(16)30580-0

PMID:27839960

Abstract

摘要

相似文献

Phase 1/2 study of blinatumomab in relapsed paediatric ALL.

Lancet Oncol. 2016 Dec;17(12):e525. doi: 10.1016/S1470-2045(16)30580-0. Epub 2016 Nov 11.

Blinatumomab significantly improves overall survival.

Lancet Oncol. 2017 Apr;18(4):e203. doi: 10.1016/S1470-2045(17)30183-3. Epub 2017 Mar 10.

Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.

Expert Rev Hematol. 2017 Dec;10(12):1057-1067. doi: 10.1080/17474086.2017.1396890. Epub 2017 Nov 1.

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Blood Cancer J. 2018 Aug 22;8(9):80. doi: 10.1038/s41408-018-0117-0.

Safety and efficacy of blinatumomab: a real world data.

Ann Hematol. 2020 Apr;99(4):835-838. doi: 10.1007/s00277-019-03854-0. Epub 2020 Feb 20.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.

A closer look at blinatumomab.

Clin Adv Hematol Oncol. 2018 Jun;16(6):412-414.

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.

Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25.

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

Ann Hematol. 2020 Oct;99(10):2215-2229. doi: 10.1007/s00277-020-04221-0. Epub 2020 Aug 27.

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.

Cancer. 2016 Jul 15;122(14):2178-85. doi: 10.1002/cncr.30031. Epub 2016 May 3.

引用本文的文献

Immunotherapy- (Blinatumomab-) Related Lineage Switch of Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.

Case Rep Hematol. 2019 Dec 7;2019:7394619. doi: 10.1155/2019/7394619. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Phase 1/2 study of blinatumomab in relapsed paediatric ALL.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献